



Pneumococcal vaccination recommendations for people who have previously received a pneumococcal vaccine

Several pneumococcal vaccines are available in Australia. The additional doses that some people are recommended to receive depend on which pneumococcal vaccine doses they have previously received.

Pneumococcal vaccination is recommended for infants and children, Aboriginal and Torres Strait Islander adults aged ≥50 years, adults aged ≥70 years and people with certain risk conditions.

These flowcharts show the recommendations for vaccinating people who have previously received a pneumococcal vaccine:

- ▶ Non-Indigenous adults aged ≥70 years without risk conditions for pneumococcal disease
- ▶ Aboriginal and Torres Strait Islander adults aged ≥50 years
- ► Children and adolescents aged ≥12 months to <18 years with risk conditions for pneumococcal disease</p>
- ► Adults aged ≥18 years with risk conditions for pneumococcal disease.

These previous doses do not include the doses received as part of the routine childhood schedule.

For information on routine vaccination in children aged <10 years, see the National Immunisation Program Schedule, the Australian Immunisation Handbook and the National Immunisation Catch-up Calculator.

Providers should verify that any previous doses have been documented, such as in the Australian Immunisation Register (AIR) or in GP records. If previous vaccination cannot be confirmed, assume that the person has not received the vaccine(s) they need.

Current pneumococcal vaccines

PCV

20-valent pneumococcal conjugate vaccine (Prevenar 20)

Registered for use in people from age

6 weeks

► NIP funded for children and adolescents aged <18 years

PCV

13-valent pneumococcal conjugate vaccine

(Prevenar 13)

Registered for use in people from age

6 weeks

NIP funded for adults aged ≥18 years

23vPPV

23-valent pneumococcal polysaccharide vaccine

(Pneumovax 23)

Registered for use in people from age

2 years

NIP funded for adults aged ≥18 years

PCV


15-valent pneumococcal conjugate vaccine

(Vaxneuvance)

- Registered for use in people from age
 - 6 weeks
- Not NIP funded


Non-Indigenous adults aged ≥70 years without <u>risk conditions for pneumococcal disease</u>

Recommended schedule: 1 dose of PCV. People in this group are no longer recommended to receive any doses of 23vPPV.



Aboriginal and Torres Strait Islander adults aged ≥50 years

Recommended schedule: 1 dose of PCV and 2 doses of 23vPPV.




Children and adolescents aged ≥12 months to <18 years with <u>risk</u> conditions for pneumococcal disease

Recommended schedule: 1 dose of 20vPCV.

Exceptions:

- ▶ Aboriginal and Torres Strait Islander children who are fully vaccinated will have already received the appropriate number of doses regardless of whether they have been diagnosed with a risk condition. No further doses are needed for these children.
- ▶ Children who have received a haematopoietic stem cell transplant are recommended to be revaccinated against pneumococcal disease, regardless of previous doses. See <u>Table. Recommendations for vaccination after</u> haematopoietic stem cell transplant in children and adults.
- ▶ Children aged <5 years with risk conditions who have not completed the childhood pneumococcal vaccination schedule should follow the catch-up schedule.



Adults aged ≥18 years with risk conditions for pneumococcal disease

Recommended schedule: 1 dose of PCV and 2 doses of 23vPPV.

Exceptions:

- ▶ Aboriginal and Torres Strait Islander adults aged ≥50 years who are fully vaccinated will have already received the appropriate number of doses regardless of whether they have been diagnosed with a risk condition. No further doses are needed for these adults.
- Adults who have received a haematopoietic stem cell transplant are recommended to be revaccinated against pneumococcal disease, regardless of previous doses. See <u>Table. Recommendations for vaccination after</u> haematopoietic stem cell transplant in children and adults.

